Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 514

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 514
---

and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits
must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation
of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances
of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Management’s Annual Report on Internal
Control Over Financial Reporting

This annual report does not
include a report of management’s assessment regarding internal control over financial reporting or an attestation report of our
independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.

Changes in Internal Control Over Financial
Reporting

There were no changes in our
internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fourth
quarter of the fiscal year covered by this annual report that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.

Not applicable.

16

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.

Directors and Executive Officers

Our directors and executive
officers are as follows:

    Name
     
    Age
     
    Title
  
    Lynn Stockwell
     
    69
     
    Chief Executive Officer and Executive Chair of the Board
  
    Glenn Worman
     
    66
     
    Chief Financial Officer
  
    Catherine Do
     
    45
     
    Director 
  
    G. Sridhar Prasad
     
    62
     
    Director 
  
    Myron W. Shulgan
     
    79
     
    Director 

Lynn Stockwell has been our Chief Executive
Officer since September 2024 and Executive Chair of the Board since June 2024 and is the managing member